Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 6/20 | 0.40 |
| ▸ | IGF2R | P11717 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.34 |
| ▸ | TOP1 | P11387 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30153685 | 0.87 | TYR (0.45) | TYRPOLBGAAMAPT | |
| SCHEMBL31053942 | 0.82 | ACHE (0.42) | TYRPOLBGAA | |
| SCHEMBL31229542 | 0.77 | TYR (0.44) | TYRPOLBGAAMAPT | |
| SCHEMBL30712748 | 0.72 | ACHE (0.46) | GAA | |
| SCHEMBL38650628 | 0.72 | ACHE (0.46) | GAA | |
| SCHEMBL10014359 | 0.69 | IGF2R (0.50) | IGF2R | |
| SCHEMBL14114844 | 0.67 | IGF2R (0.52) | TYRIGF2RPOLBNR1H4SELE | |
| SCHEMBL18870467 | 0.67 | IGF2R (0.52) | TYRIGF2RPOLBNR1H4SELE | |
| SCHEMBL25566551 | 0.67 | IGF2R (0.50) | IGF2RPOLBMAPT | |
| SCHEMBL31253175 | 0.67 | POLB (0.46) | TYRPOLBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622874-B2 | Trans-crocetin compositions and treatment regimens | L.E.A.F. HOLDINGS GROUP LLC (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260014079-A1 | CAROTENOID COMPOSITIONS AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12523655-B2 | Leaf markers for root colonization by arbuscular mycorrhizal fungi in plants | MAX PLANCK GESELLSCHAFT (DE) | 2026-01-13 | — | — | US | disclosed |
| EP-4667017-A2 | CAROTENOID COMPOSITIONS AND USES THEREOF | L.E.A.F Holdings Group LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-3787607-B1 | CAROTENOID COMPOSITIONS AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12458597-B2 | Carotenoid compositions and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-11-04 | — | — | US | disclosed |
| CN-119185280-A | Carotenoid composition and use thereof | L.E.A.F.控股集团公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240350446-A1 | CAROTENOID SOLUTIONS AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2024-10-24 | — | — | US | disclosed |
| CN-112236134-B | Carotenoid composition and use thereof | L.E.A.F.控股集团公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-111787787-B | Leaf markers for root colonization of plants by arbuscular mycorrhizal fungi | 马克思—普朗克科学促进协会公司 | 2023-10-03 | — | — | CN | disclosed |
| US-20230277494-A1 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | L E A F HOLDINGS GROUP LLC (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230270706-A1 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | L E A F HOLDINGS GROUP LLC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230210803-A1 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | L E A F HOLDINGS GROUP LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230134835-A1 | METHODS OF SYNTHESIZING CAROTENOIDS | L E A F HOLDINGS GROUP LLC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20220409565-A1 | CAROTENOID COMPOSITIONS AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458597-B2 | Carotenoid compositions and uses thereof | STARD7, LRAT, HCCS | TYR 3000/4885IGF2R 4216/4885POLB 3862/4885 |
| US-12622874-B2 | Trans-crocetin compositions and treatment regimens | CPT2, SOD1, TFRC | TYR 3416/4885IGF2R 3531/4885POLB 4406/4885 |
| US-20230277494-A1 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | TTPA, HIF1A, HIF1AN | TYR 4411/4885IGF2R 4542/4885POLB 3892/4885 |
| US-20220409565-A1 | CAROTENOID COMPOSITIONS AND USES THEREOF | STARD7, LRAT, HCCS | TYR 3000/4885IGF2R 4216/4885POLB 3862/4885 |
| US-20230210803-A1 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | TTPA, HIF1A, HIF1AN | TYR 4509/4885IGF2R 4626/4885POLB 3799/4885 |
| US-20230270706-A1 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | TTPA, HIF1A, CPT1A | TYR 4426/4885IGF2R 4427/4885POLB 4251/4885 |
| US-20260014079-A1 | CAROTENOID COMPOSITIONS AND USES THEREOF | STARD7, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPT2 | TYR 4052/4885IGF2R 3834/4885POLB 3333/4885 |
| US-20230134835-A1 | METHODS OF SYNTHESIZING CAROTENOIDS | HCCS, GYS2, GYS1 | TYR 2801/4885IGF2R 4465/4885POLB 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.